- Home
- SLN vs AEF Comparison
SLN vs AEF Comparison
Compare SLN & AEF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- AEF
- Stock Information
- Founded
- SLN 1994
- AEF 1989
- Country
- SLN United Kingdom
- AEF United States
- Employees
- SLN N/A
- AEF N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- AEF Finance/Investors Services
- Sector
- SLN Health Care
- AEF Finance
- Exchange
- SLN Nasdaq
- AEF Nasdaq
- Market Cap
- SLN 345.3M
- AEF 277.7M
- IPO Year
- SLN N/A
- AEF N/A
- Fundamental
- Price
- SLN $6.67
- AEF $6.70
- Analyst Decision
- SLN Buy
- AEF
- Analyst Count
- SLN 6
- AEF 0
- Target Price
- SLN $39.67
- AEF N/A
- AVG Volume (30 Days)
- SLN 212.8K
- AEF 92.5K
- Earning Date
- SLN 11-06-2025
- AEF 01-01-0001
- Dividend Yield
- SLN N/A
- AEF 7.13%
- EPS Growth
- SLN N/A
- AEF N/A
- EPS
- SLN N/A
- AEF 0.57
- Revenue
- SLN $25,830,000.00
- AEF N/A
- Revenue This Year
- SLN N/A
- AEF N/A
- Revenue Next Year
- SLN N/A
- AEF N/A
- P/E Ratio
- SLN N/A
- AEF $8.86
- Revenue Growth
- SLN 40.39
- AEF N/A
- 52 Week Low
- SLN $1.97
- AEF $4.40
- 52 Week High
- SLN $8.88
- AEF $5.53
- Technical
- Relative Strength Index (RSI)
- SLN 55.39
- AEF 51.82
- Support Level
- SLN $5.91
- AEF $6.41
- Resistance Level
- SLN $6.62
- AEF $6.99
- Average True Range (ATR)
- SLN 0.51
- AEF 0.11
- MACD
- SLN -0.05
- AEF -0.03
- Stochastic Oscillator
- SLN 81.25
- AEF 49.41
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
About AEF abrdn Emerging Markets Equity Income Fund Inc.
ABERDEEN EMERGING MARKETS EQUITY INCOME FUND, INC. is a closed-end investment company. The Fund's investment objective is to seek to provide both current income and long-term capital appreciation. The Fund invests in a range of sectors, including financials, consumer staples, utilities, consumer discretionary, materials, energy, information technology, private equity, communication services, healthcare, real estate, and industrials.